Amber with Guidance= To be initiated and titrated to a stable dose in secondary care with follow up prescribing and monitoring by primary care where deemed appropriate.







Disulfiram

Background Information	Disulfiram is used as an adjunct in the treatment of alcohol dependence. It gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol because it causes accumulation of acetaldehyde in the body; it is only effective if taken daily. Symptoms can occur within 10 minutes of ingesting alcohol and include flushing of the face, throbbing headache, palpitation, tachycardia, nausea, vomiting, and, with large doses of alcohol, arrhythmias, hypotension, and collapse; these reactions can last several hours. Small amounts of alcohol such as those included in many oral medicines may be sufficient to precipitate a reaction—even toiletries and mouthwashes that contain alcohol should be avoided. If this reaction occurs the patient should seek medical advice and a reaction should be treated in hospital. Alcohol should be avoided for at least 1 week after stopping treatment.		
	Before initiating disulfiram, prescribers should evaluate the patient's suitability for treatment, because some patient factors, for example memory impairment or social circumstances, make compliance to treatment or abstinence from alcohol difficult.		
BNF therapeutic class	4.10. Drugs used in substance dependence https://doi.org/10.18578/BNF.400566415		
Indication	Adjunct in the treatment of alcohol dependence (under expert supervision)		
Dosage and administration	The standard dose is 200mg daily. Dose can be increased up to 500mg if necessary There is no need for a loading dose to start treatment. The treatment is usually continued for approximately 6 – 12 months but some patients wish to continue for longer. There is no reason why disulfiram cannot be continued if well tolerated.		
Cautions and Contraindications	The following are cautions to disulfiram and require discussion with the team, the prescriber and the patient in balancing the risk and benefits of treatment. Liver disease Moderately elevated liver function tests (>x 2 ALT) Epilepsy Diabetes Acute porphyrias Respiratory disease Contraindications: Coronary artery disease History of stroke Hypertension (uncontrolled) Psychosis High suicidal risk Renal failure Pregnancy or breast feeding Severe Personality Disorder Contra-indications are not absolute. There will be cases where the known risks of continuing to drink alcohol will outweigh the potential risk of prescribing. If prescribing goes ahead after assessing the risks/benefits, reasons should be clearly documented.		

Disulfiram Guidance Page 1 of 2

Review Date: October 2022

Date Approved: October 2020

Amber with Guidance= To be initiated and titrated to a stable dose in secondary care with follow up prescribing and monitoring by primary care where deemed appropriate.

Adverse Drug Reactions	Side-effects: These are usually mild and transient. The most common are gastro-intestinal symptoms.			
	Side Effect	Suggested Action		
	Drowsiness/fatigue	Take at night, usually lessens		
	Nausea/vomiting	Take after food		
	Halitosis	Ensure dental hygiene		
	Sexual dysfunction/lack of libido	Discuss with doctor, may be another cause		
	Mood changes	Discuss		
	Impaired liver function	Need to monitor LFT, may need to discontinue		
Monitoring	Initiation and initial monitoring should be by a specialist service (Substance Misuse Team or Shared care GP practices). Patients should be seen every 2 weeks for the first 2 months, then monthly for the following 4 months. It is desirable for a carer or family member who is aware of the use of disulfiram to oversee its administration. It is recommended that the liver function count is checked 1-2 months after starting treatment (specialist responsibility) and then every 6 months if within normal parameters. Disulfiram should be discontinued if there is any evidence of symptomatic liver disease.			
Interactions	Important to check reactions in BNF with: Warfarin Phenytoin Benzodiazepines – metabolism is inhibited, increasing sedative effect Amitriptyline and other tricyclic antidepressants Metronidazole			

Contact names and details

Contact Details	Telephone number	Email
Dr Fleur Ashby Consultant Clinical Director, Barnsley Recovery Steps	01226 779066	Amanda.Ashby@humankindcharity.org.uk
Chris Lawson, Head of Medicines Management, NHS Barnsley CCG	01226 433798	chris.lawson@nhs.net

References

- British National Formulary. Available at: https://www.medicinescomplete.com/mc/bnf/current/index.htm Accessed 12.08.20
- Disulfiram Summary of Product Characteristics March 2020. Available at: https://www.medicines.org.uk/emc/product/11168 Accessed 12.08.20
- Alcohol Use Disorders. Diagnosis, assessment and management of harmful drinking and alcohol dependence. NICE Clinical Guideline 115. February 2011. Available at: http://guidance.nice.org.uk/CG115 Accessed 12.08.20
- Choice and Medication website (information about mental health conditions, treatments and medications). Available at: https://www.choiceandmedication.org/humankind/

This guideline was approved at the APC on 14th October 2020.

Disulfiram Guidance Page 2 of 2

Review Date: October 2022

Date Approved: October 2020